コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ing the downstream signaling of the vascular endothelial growth factor receptor.
2 least partly distinct from that of vascular endothelial growth factor receptor.
3 ibitor that preferentially inhibits vascular endothelial growth factor receptors.
5 ucleotide polymorphism (SNP) in the vascular endothelial growth factor receptor 1 (VEGFR-1/Flt1) prom
6 inflammatory cells--might depend on vascular endothelial growth factor receptor 1 (VEGFR1) activity.
7 significance, including Ki67, p53, vascular endothelial growth factor receptor 1 (VEGFR1) and ligand
8 hes, we show that the expression of vascular endothelial growth factor receptor 1 (VEGFR1) by pericyt
10 ective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -
11 say and the increased expression of vascular endothelial growth factor receptor 1 (VEGFR1), an HIF-re
12 imal seventh Ig-like domain (D7) of vascular endothelial growth factor receptor 1 (VEGFR1), VEGFR2, a
13 CXCR7 expression and recruitment of vascular endothelial growth factor receptor 1 (VEGFR1)-expressing
14 study sought to determine whether a Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-specific m
15 study sought to determine whether a vascular endothelial growth factor receptor 1 (VEGFR1)-specific m
16 receptor 2 antibody) or icrucumab (vascular endothelial growth factor receptor 1 antibody) after pro
17 lacental growth factor, and soluble vascular endothelial growth factor receptor 1 levels were poor pr
18 atopoietic progenitors that express vascular endothelial growth factor receptor 1 mobilize in respons
19 h factor A (VEGF-A) and the soluble vascular endothelial growth factor receptor 1 molecule, which bin
20 rmation (evidenced by a decrease in vascular endothelial growth factor receptor 1 positive (VEGFR1(+)
21 -like tyrosine kinase 1 (sFlt-1) of vascular endothelial growth factor receptor 1 secreted from the p
22 ranscriptional induction of Vegfr1 (vascular endothelial growth factor receptor 1) is dependent on th
23 endothelial growth factor A and D; vascular endothelial growth factor receptor 1, 2, and 3; osteopon
24 lternatively spliced variant of the vascular endothelial growth factor receptor 1, induces a preeclam
25 Cediranib is an oral antiangiogenic vascular endothelial growth factor receptor 1-3 inhibitor that ha
26 nic factors promote mobilization of vascular endothelial growth factor receptor 1-positive hematopoie
27 that PlGF acts through Nrp1-and not vascular endothelial growth factor receptor 1-to promote tumor ce
30 y; with placental growth factor and vascular endothelial growth factor receptors 1 and 2 using revers
31 ine kinase activity associated with vascular endothelial growth factor receptors 1, 2, and 3, current
32 Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibrobl
33 l, orally bioavailable inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, platele
34 anib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platele
40 results in the secretion of soluble vascular endothelial growth factor receptor-1 (VEGFR-1/sFlt-1), w
43 lt-1 (sFlt-1; also known as soluble vascular endothelial growth factor receptor-1 [VEGFR-1]) and solu
44 oma stem cell-associated nestin and vascular endothelial growth factor receptor-1 also was documented
45 ow-derived (BMD) cells that express vascular endothelial growth factor receptor-1 and very late antig
46 istant core fragment comprising the vascular endothelial growth factor receptor-1 binding site but la
47 was true for the finding of higher vascular endothelial growth factor receptor-1 expression in conju
49 ib, which is a potent and selective vascular endothelial growth factor receptor-1, -2, and -3 inhibit
52 DNA minigene vaccine against murine vascular endothelial growth factor receptor 2 (FLK-1), a self-ant
53 idermal growth factor receptor, and vascular endothelial growth factor receptor 2 (Flk-1), but not CD
54 ent studies have shown that soluble vascular endothelial growth factor receptor 2 (sVEGFR2), VEGF, an
55 Ptrend = 1.1 x 10(-6)), and soluble vascular endothelial growth factor receptor 2 (sVEGFR2; OR, 2.3;
56 ) pathways and the up-regulation of vascular endothelial growth factor receptor 2 (VEGF-R2) and focal
57 abnormal and persistent increase in vascular endothelial growth factor receptor 2 (VEGF-R2) expressio
58 gets the key angiogenesis receptors vascular endothelial growth factor receptor 2 (VEGFR-2) and fibro
59 embryonic stem cells, the onset of vascular endothelial growth factor receptor 2 (VEGFR-2) expressio
60 tom designed imaging probes against vascular endothelial growth factor receptor 2 (VEGFR-2) in retina
61 pharmacokinetics, and estimation of vascular endothelial growth factor receptor 2 (VEGFR-2) phosphory
62 ithelial growth factor receptor and vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine
63 internalization and degradation of vascular endothelial growth factor receptor 2 (VEGFR-2), a potent
64 s, improves EC survival mediated by vascular endothelial growth factor receptor 2 (VEGFR-2), angiogen
65 or E-selectin, and EPCs expressing vascular endothelial growth factor receptor 2 (VEGFR-2), CD133, a
67 or receptor 2-IIIb (FGFR2b) and the vascular endothelial growth factor receptor 2 (VEGFR2) are tyrosi
69 matopoietic cell loss of FGFR1/2 or vascular endothelial growth factor receptor 2 (Vegfr2) haploinsuf
70 ease is resistant to treatment with vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor.
71 own to have a high affinity for the vascular endothelial growth factor receptor 2 (VEGFR2) is describ
74 Cdc42 in ECs decreased the level of vascular endothelial growth factor receptor 2 (VEGFR2) protein on
75 tyrosine phosphatase (SHP)-1 to the vascular endothelial growth factor receptor 2 (VEGFR2) signaling
76 kinase (Etk), which trans-activates vascular endothelial growth factor receptor 2 (VEGFR2) to promote
77 class of potent and selective human vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine k
78 sed on an amyloidogenic fragment of vascular endothelial growth factor receptor 2 (VEGFR2), a protein
79 inib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET,
81 eceptor tyrosine kinases, including vascular endothelial growth factor receptor 2 (VEGFR2), platelet-
83 ermeabilizing responses directed by vascular endothelial growth factor receptor 2 (VEGFR2), we found
84 y this strategy to the isolation of vascular endothelial growth factor receptor 2 (VEGFR2)-binding pe
85 ors, PRAK is activated by p38 via a vascular endothelial growth factor receptor 2 (VEGFR2)-dependent
86 graphy (US) by using clinical-grade vascular endothelial growth factor receptor 2 (VEGFR2)-targeted m
90 rom a population that expresses the vascular endothelial growth factor receptor 2 (VEGFR2, Flk-1), su
91 ase inhibitor with activity against vascular endothelial growth factor receptor 2 and epidermal growt
92 hat GA inhibited the activations of vascular endothelial growth factor receptor 2 and its downstream
93 giogenic receptor tyrosine kinases, vascular endothelial growth factor receptor 2 and platelet-derive
96 el in combination with ramucirumab (vascular endothelial growth factor receptor 2 antibody) or icrucu
97 d to a significant up-regulation of vascular endothelial growth factor receptor 2 expression and cell
98 pidermal growth factor receptor and vascular endothelial growth factor receptor 2 expression differed
99 gnificantly lower proliferation and vascular endothelial growth factor receptor 2 expression levels w
100 ies point to the key role played by vascular endothelial growth factor receptor 2 in control of this
101 Wnt10b stimulated expression of vascular endothelial growth factor receptor 2 in endothelial cell
102 On endothelial cells, integrins and vascular endothelial growth factor receptor 2 influence the activ
104 e fused polypeptides from the mouse vascular endothelial growth factor receptor 2 molecule (fetal liv
105 provides insights into how FLT1 and vascular endothelial growth factor receptor 2 signaling is titrat
106 dothelial nitric oxide synthase/Akt/vascular endothelial growth factor receptor 2 signaling, and a re
108 al cells, we immunized against host vascular endothelial growth factor receptor 2 to fight the growth
109 he combination of anti-TLR2 and antivascular endothelial growth factor receptor 2 yielded an additive
111 r engrailed repressed expression of Vascular Endothelial Growth Factor Receptor 2, a marker of endoth
112 tion of subsets coexpressing CD133, vascular endothelial growth factor receptor 2, and chemokine (C-X
113 -smooth muscle actin, CD31, phospho-vascular endothelial growth factor receptor 2, and p42/44 mitogen
114 ocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged dur
115 e endothelial cells expressed CD31, vascular endothelial growth factor receptor 2, and von Willebrand
116 onocytes expressed F4/80, CD31, and vascular endothelial growth factor receptor 2, but neither CD133
118 of neutralizing antibodies against vascular endothelial growth factor receptor 2, CCR3, CC chemokine
119 inib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and i
120 mely matrix metalloproteinase 1 and vascular endothelial growth factor receptor 2, were negatively re
121 ossibly involved in mobilization of vascular endothelial growth factor receptor 2-positive endothelia
128 dothelial nitric oxide synthase/Akt/vascular endothelial growth factor receptor 2/oxidative stress-in
129 lar endothelial growth factors A/C, vascular endothelial growth factor receptors 2/3, angiopoietin 1/
131 or a truncated soluble form of the vascular endothelial growth factor receptor-2 (truncated soluble
132 ted two compounds that each inhibit vascular endothelial growth factor receptor-2 (VEGFR-2) and plate
133 el PET imaging agents for assessing vascular endothelial growth factor receptor-2 (VEGFR-2) expressio
134 ose- and time-dependent decrease in vascular endothelial growth factor receptor-2 (VEGFR-2) immunorea
135 hospholipase Cgamma1 (PLCgamma1) by vascular endothelial growth factor receptor-2 (VEGFR-2) in endoth
137 potent and selective inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2) kinase ac
138 splice variant of the gene encoding vascular endothelial growth factor receptor-2 (Vegfr-2) that enco
139 ved growth factor receptor-beta and vascular endothelial growth factor receptor-2 (VEGFR-2) were over
140 rent antibodies [anti-CD34, -CD31, -vascular endothelial growth factor receptor-2 (VEGFR-2), -CD146,
145 differentiation 34 (CD34+) or CD34+/vascular endothelial growth factor receptor-2 (VEGFR2+) counts wa
146 hemokine requires the activation of vascular endothelial growth factor receptor-2 (VEGFR2/fetal liver
147 ogenesis requires the activation of vascular endothelial growth factor receptor-2 (VEGFR2/Flk-1/KDR).
148 from signal transducing full-length vascular endothelial growth factor receptor-2 (VEGFR2/KDR) to a d
149 munoglobulin G1 antibody that binds vascular endothelial growth factor receptor-2 and blocks ligand-s
150 nonclassical pathway dependent upon vascular endothelial growth factor receptor-2 and downstream seco
151 b is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growt
152 was required for the expression of vascular endothelial growth factor receptor-2 and fibroblast grow
153 ugh modulation of the expression of vascular endothelial growth factor receptor-2 and fibroblast grow
154 nown to induce Notch, by repressing vascular endothelial growth factor receptor-2 and neuropilin-1.
155 d macrophages were able to activate vascular endothelial growth factor receptor-2 and the PI3K/serine
156 JAK/STAT-dependent up-regulation of vascular endothelial growth factor receptor-2 by sIL-6R alpha/IL-
157 eased, whereas endoglin and soluble vascular endothelial growth factor receptor-2 decreased (P < .01;
159 helial growth factor expression and vascular endothelial growth factor receptor-2 expression on large
160 is less prominent, but downregulation of the endothelial growth factor receptor-2 gene, resulting in
161 face expression of CD133, CD34, and vascular endothelial growth factor receptor-2 in 110 patients und
162 [1,2,4]triazine-based inhibitors of vascular endothelial growth factor receptor-2 kinase is reported.
164 tering alpha(v)beta(3) integrin and vascular endothelial growth factor receptor-2 trafficking, thereb
165 tion/dissociation rate constants of vascular endothelial growth factor receptor-2 with respect to a m
166 OG which mediates the expression of vascular endothelial growth factor receptor-2, also known as feta
167 clear cells expressing CD34, CD133, vascular endothelial growth factor receptor-2, and chemokine (C-X
168 Vandetanib selectively targets RET, vascular endothelial growth factor receptor-2, and epidermal grow
169 els in mammary tumours, by blocking vascular endothelial growth factor receptor-2, improves the deliv
170 ted against various targets such as vascular endothelial growth factor receptor-2, vascular cell adhe
173 istence of a new soluble isoform of vascular endothelial growth factor receptor 3 (sVEGFR-3), which i
174 is by monoclonal antibodies against vascular endothelial growth factor receptor 3 (VEGFR-3) ameliorat
175 expression of the lymphatic markers vascular endothelial growth factor receptor 3 (VEGFR-3) and podop
176 of mF4-31C1, a specific antagonist vascular endothelial growth factor receptor 3 (VEGFR-3) antibody
177 lar endothelial growth factor C and vascular endothelial growth factor receptor 3 (VEGFR-3) are the m
178 and after 8 weeks of treatment with vascular endothelial growth factor receptor 3 (VEGFR-3) neutraliz
181 e bearing one inactivated allele of vascular endothelial growth factor receptor 3 (VEGFR3) where skin
182 aotic and poorly formed and express vascular endothelial growth factor receptor 3 (VEGFR3), a growth
183 interaction between PTPN14 and the vascular endothelial growth factor receptor 3 (VEGFR3), a recepto
184 locked several receptors, including vascular endothelial growth factor receptor 3 (VEGFR3), the major
188 rs (prospero homeobox protein 1 and vascular endothelial growth factor receptor 3) as well as blood e
189 lial hyaluronan receptor 1-positive vascular endothelial growth factor receptor 3-positive lymphatic
190 myocardial-targeted delivery of the vascular endothelial growth factor receptor 3-selective designer
192 mediators of lymphangiogenesis are vascular endothelial growth factor receptor-3 (VEGFR-3) and Prox1
193 Focal adhesion kinase (FAK) and vascular endothelial growth factor receptor-3 (VEGFR-3) are prote
194 part, associated with inhibition of vascular endothelial growth factor receptor-3 (VEGFR-3) expressio
195 The results identified elevated vascular endothelial growth factor receptor-3 short form splice v
196 amethasone but not by inhibition of vascular endothelial growth factor receptor-3 signaling by antibo
197 ether combined blockade of VEGFR-3 (vascular endothelial growth factor receptor-3) and VLA-1 (very la
198 mphatic marker genes podoplanin and vascular endothelial growth factor receptor-3, which is mediated
200 b is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth
201 ing rearranged during transfection, vascular endothelial growth factor receptor and epidermal growth
202 is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth
203 tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor and fibroblast growth
204 or tyrosine kinase inhibitor of the vascular endothelial growth factor receptor and multiple other gr
206 the tyrosine kinase activity of the vascular endothelial growth factor receptor and the platelet-deri
207 se inhibitors that target RET, plus vascular endothelial growth factor receptors and additional kinas
208 yrosine kinase inhibitors targeting vascular endothelial growth factor receptors and RET (rearranged
209 daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth
210 a selective oral inhibitor of RET, vascular endothelial growth factor receptor, and epidermal growth
211 let-derived growth factor receptor, vascular endothelial growth factor receptor, and epidermal growth
212 bitor of kinases, including MET and vascular endothelial growth factor receptors, and has shown activ
213 se each of plastic microspheres and vascular endothelial growth factor receptor antagonist in polysty
214 e tyrosine kinase inhibitors of the vascular endothelial growth factor receptor are under investigati
216 h pulmonary hypertension induced by vascular endothelial growth factor receptor blockade and hypoxia
217 tor, EphA2, versus control animals, vascular endothelial growth factor receptor blockade and hypoxia
219 ingle subcutaneous injection of the vascular endothelial growth factor receptor blocker Sugen 5416, r
220 sine kinase inhibitor that inhibits vascular endothelial growth factor receptor, c-KIT, and PDGFR, an
221 tikinase inhibitor of AXL, MET, and vascular endothelial growth factor receptor currently in phase II
222 provide a basis for the activity of vascular endothelial growth factor receptor-directed therapy in t
223 ne kinase inhibitors targeting RET, vascular endothelial growth factor receptor, epidermal growth fac
224 lular proliferation, migration, and vascular endothelial growth factor receptor expression and induce
225 helial growth factor and of soluble vascular endothelial growth factor receptor Flt1 (sFlt1) were mea
226 for vascular development, including vascular endothelial growth factor receptors Flt1 and Flk1, Pdgfb
228 e polymorphisms in the 3'UTR of the vascular endothelial growth factor receptor/FLT1, E2F2 and PCM1 o
229 mammalian target of rapamycin, and vascular endothelial growth factor receptor have all shown effica
230 othelial growth factor signaling by vascular endothelial growth factor receptor inhibition may comple
231 logue (everolimus) and an epidermal/vascular endothelial growth factor receptor inhibitor (AEE788) we
232 after subcutaneous injection of the vascular endothelial growth factor receptor inhibitor SUGEN 5416.
233 ntially benefit from small-molecule vascular endothelial growth factor receptor inhibitor therapy has
234 aluate trebananib plus sunitinib, a vascular endothelial growth factor receptor inhibitor, in patient
235 0 mg of sorafenib, a Raf kinase and vascular endothelial growth factor receptor inhibitor, per kilogr
236 ved endothelial cells, defects in a vascular endothelial growth factor receptor/integrin complex redu
237 hrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes.
239 rmal growth factor receptor and the vascular endothelial growth factor receptor on tumor cells and st
240 rmal growth factor receptor family, vascular endothelial growth factor receptor or DNA damage respons
241 Vascularization in response to anti-vascular endothelial growth factor receptor or vehicle-control tr
242 racting protein-1 prevented 20-HETE-mediated endothelial growth factor receptor phosphorylation and a
243 nts showed a reduction in levels of vascular endothelial growth factor receptor phosphorylation, ERK
244 osine kinase inhibitors that target vascular endothelial growth factor receptor, platelet-derived gro
245 by sorafenib, including Raf kinase, vascular endothelial growth factor receptors, platelet-derived gr
246 that short-term treatment with the vascular endothelial growth factor receptor/platelet-derived grow
247 etalloprotease domain 17 (ADAM-17), vascular endothelial growth factor receptors, Polo-like kinase 1,
248 platelet-derived growth factor- and vascular endothelial growth factor-receptor (Pvr) homologue.
249 lar lesion is mediated by a soluble vascular endothelial growth factor receptor that deprives glomeru
250 ial growth factor receptor (VEGFR), vascular endothelial growth factor receptor type 1 (VEGFR1), vasc
251 e possible localization and role of vascular endothelial growth factor receptor type 2 (VEGFR2) in th
252 to investigate treatment effects on vascular endothelial growth factor receptor type 2 (VEGFR2) phosp
253 th factor receptor type 1 (VEGFR1), vascular endothelial growth factor receptor type 2 (VEGFR2), and
254 aging using clinically translatable vascular endothelial growth factor receptor type 2 (VEGFR2)-targe
255 lar endothelial growth factor-a and vascular endothelial growth factor receptor type 2 in the infarct
256 actor receptor type 2 (VEGFR2), and vascular endothelial growth factor receptor type 3 (VEGFR3).
257 es revolve around inhibition of the vascular endothelial growth factor receptor tyrosine kinase and t
259 trategy to circumvent resistance to vascular endothelial growth factor receptor tyrosine kinase inhib
262 sis and lymphangiogenesis involving vascular endothelial growth factor-receptor tyrosine kinase and T
264 tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2,
266 tions in the RET proto-oncogene and vascular endothelial growth factor receptor (VEGFR) activity are
267 al multikinase inhibitors targeting vascular endothelial growth factor receptor (VEGFR) and approved
268 b is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal
269 that potently inhibited a panel of vascular endothelial growth factor receptor (VEGFR) and platelet-
270 potent small molecule inhibitors of vascular endothelial growth factor receptor (VEGFR) and platelet-
271 on that potently inhibited both the vascular endothelial growth factor receptor (VEGFR) and platelet-
272 c receptor tyrosine kinases (RTKs)--vascular endothelial growth factor receptor (VEGFR) and platelet-
273 endothelial growth factor (VEGF) to vascular endothelial growth factor receptor (VEGFR) and VEGF to b
274 Here we studied the role of the vascular endothelial growth factor receptor (VEGFR) in experiment
275 l growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) inhibitor-in
276 FINDINGS: Recent studies with oral vascular endothelial growth factor receptor (VEGFR) inhibitors su
277 tivator of transcription (STAT) and vascular endothelial growth factor receptor (VEGFR) signaling pat
280 Sunitinib and sorafenib are oral vascular endothelial growth factor receptor (VEGFR) tyrosine kina
282 Sunitinib and sorafenib are oral vascular endothelial growth factor receptor (VEGFR) tyrosine-kina
283 b is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal gr
284 sine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet-der
285 m vascular tumors were stained with vascular endothelial growth factor receptor (VEGFR), vascular end
286 lar endothelial growth factor-A and vascular endothelial growth factor receptor (VEGFR)-2 and is asso
289 hospholipase Cgamma1 (PLCgamma1) by vascular endothelial growth factor receptor (VEGFR)-2 is necessar
290 cells, CD47 interacts directly with vascular endothelial growth factor receptor (VEGFR)-2, and TSP1 i
291 se, distribution, and dependence on vascular endothelial growth factor receptor (VEGFR)-2/VEGFR-3 sig
292 isolated by FACS for expression of vascular endothelial growth factor receptor (VEGFR)2 and platelet
293 ral, potent, selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2, and
294 potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3
295 argeting Raf and other kinases (ie, vascular endothelial growth factor receptor [VEGFR], platelet-der
296 growth factor-A (VEGF-A) acts via 2 vascular endothelial growth factor receptors, VEGFR-1 and VEGFR-2
297 isting of PECAM-1, VE-cadherin, and vascular endothelial growth factor receptors (VEGFRs) that reside
300 l growth factor with bevacizumab or vascular endothelial growth factor receptor with oral tyrosine ki
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。